BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 36598329)

  • 21. Tolfenamic acid negatively regulates YAP and TAZ expression in human cancer cells.
    Kim I; Lertpatipanpong P; Yoon Y; Lee J; Hong Y; Boonruang K; Ryu J; Baek SJ
    Biochim Biophys Acta Mol Cell Res; 2023 Dec; 1870(8):119556. PubMed ID: 37544381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
    Kim M; Kim T; Johnson RL; Lim DS
    Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arhgef7 promotes activation of the Hippo pathway core kinase Lats.
    Heidary Arash E; Song KM; Song S; Shiban A; Attisano L
    EMBO J; 2014 Dec; 33(24):2997-3011. PubMed ID: 25425573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
    Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
    Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heat stress activates YAP/TAZ to induce the heat shock transcriptome.
    Luo M; Meng Z; Moroishi T; Lin KC; Shen G; Mo F; Shao B; Wei X; Zhang P; Wei Y; Guan KL
    Nat Cell Biol; 2020 Dec; 22(12):1447-1459. PubMed ID: 33199845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer.
    Wang D; Li Z; Li X; Yan C; Yang H; Zhuang T; Wang X; Zang Y; Liu Z; Wang T; Jiang R; Su P; Zhu J; Ding Y
    J Exp Clin Cancer Res; 2022 Jul; 41(1):219. PubMed ID: 35820928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
    Nishina H
    Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
    Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
    BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The novel YAP target gene, SGK1, upregulates TAZ activity by blocking GSK3β-mediated TAZ destabilization.
    Yoo G; Kim T; Chung C; Hwang DS; Lim DS
    Biochem Biophys Res Commun; 2017 Aug; 490(3):650-656. PubMed ID: 28634071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
    Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
    Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
    Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
    Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 35. Identification of Prolyl isomerase Pin1 as a novel positive regulator of YAP/TAZ in breast cancer cells.
    Khanal P; Yeung B; Zhao Y; Yang X
    Sci Rep; 2019 Apr; 9(1):6394. PubMed ID: 31015482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. YAP and TAZ play a crucial role in human erythrocyte maturation and enucleation.
    Damkham N; Lorthongpanich C; Klaihmon P; Lueangamornnara U; Kheolamai P; Trakarnsanga K; Issaragrisil S
    Stem Cell Res Ther; 2022 Sep; 13(1):467. PubMed ID: 36076260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.
    Li H; Gumbiner BM
    Mamm Genome; 2016 Dec; 27(11-12):556-564. PubMed ID: 27601049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An overview of signaling pathways regulating YAP/TAZ activity.
    Heng BC; Zhang X; Aubel D; Bai Y; Li X; Wei Y; Fussenegger M; Deng X
    Cell Mol Life Sci; 2021 Jan; 78(2):497-512. PubMed ID: 32748155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.